CA-XSOLLA
7.3.2024 14:01:26 CET | Business Wire | Press release
Xsolla, a global video game commerce company, announces Xsolla Wallet, highlighting its commitment to empowering the global creator economy within the video game industry. Our mission is to provide equal access for developers, creators, and everyone in the creator economy with embedded finance solutions for the video game industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240307401699/en/
(Graphic: Xsolla)
The Xsolla Wallet is a game-changing solution offering embedded finance options specifically designed for developers and creators. The initiative helps developers overcome monetization and engagement challenges and simplifies the process of providing attractive incentives for creators. It enhances the efficiency and immediacy of their earning and spending experience while ensuring global compliance.
Recognizing the complexities of managing successful global creator programs, Xsolla will help alleviate these pain points, enabling developers to focus on what they do best: creating engaging gaming experiences.
For Developers: Xsolla Wallet simplifies access to embedded finance services and streamlines onboarding and compliance, integrating these critical aspects within the creators' wallet accounts.
- Simplify Creator Incentives: Tailored to ease the complexities of managing creator programs, Xsolla Wallet ensures developers can provide attractive and compliant earnings for creators across different regions.
- Ease Compliance Burdens: With integrated KYC (Know Your Customer) and tax interview services, Xsolla Wallet significantly reduces the complexity associated with global compliance, allowing developers to focus on innovation rather than administrative tasks.
- Expand and Accelerate Influence: Leveraging the vast reach of the Xsolla gaming ecosystem, developers can use the Xsolla Partner Network (XPN) to attract, manage and incentivize creators and influencers.
For Creators: Xsolla Wallet empowers creators and influencers to pay, get paid and manage earnings, transforming their content into viable revenue sources.
- Pay: Creators will have a direct, immediate, and convenient way to spend their earnings using the Xsolla Mastercard.
- Get Paid: Creators can choose an instant virtual Xsolla Mastercard, amongst other payout options, to enable easy and immediate access to their earnings.
- Manage Earnings: Creators can seamlessly aggregate their earnings from platforms. This means creators can manage diverse income streams, from merchandise sales to crowdfunding, in their Xsolla Wallet.
"By bringing together our expertise and the Xsolla Wallet's embedded finance functionality, we are bringing developers and creators together in an unparalleled financial ecosystem tailored for video games," described David Stelzer, President of Xsolla. "We aim to provide an equal opportunity for every developer, creator, and influencer to have fast and secure access to ways to monetize their work in the global creator economy."
“As a long-standing supporter of the video gaming community, Mastercard is thrilled to continue building on our partnership with Xsolla, delivering choice and value to creators and developers alike with the launch of the Xsolla Mastercard,” said Sherri Haymond, EVP, Global Digital Partnerships at Mastercard. “Together we’re enabling convenient, seamless payments options that add tools to developers’ toolkits, help solve challenges for creators and foster an inclusive gaming community for all.”
Xsolla Wallet is a key component in a new suite of tools empowering game developers and creators. It reflects Xsolla's dedication to creating solutions that address content creators' immediate needs and foster a more supportive and productive environment for their creations through an embedded finance partnership with Paysafe and a card for creators partnership with Mastercard.
"We are proud to strengthen our partnership with Xsolla to provide value and exceed customer expectations with our payment solutions, further enhancing gamers' playing and payment experience globally," said Aaron Gale, VP of Sales & Account Management, Video Games at Paysafe. "Every gaming experience starts with a payment, and we are dedicated to turning these transactions into part of the overall experience, to fuel the fun and champion customer engagement and loyalty."
For more details about Xsolla Wallet, please visit: xsolla.pro/wallet
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in London, Berlin, Seoul, Beijing, Kuala Lumpur, Tokyo, and cities around the world, Xsolla supports major gaming titles like Valve, Twitch, Roblox, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit: xsolla.com
About Paysafe
Paysafe Limited (“Paysafe”) (NYSE: PSFE) (PSFE.WS) is a leading payments platform with an extensive track record of serving merchants and consumers in the global entertainment sectors. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through industry-leading capabilities in payment processing, digital wallet, and online cash solutions. With over 20 years of online payment experience, an annualized transactional volume of over $130 billion in 2022, and approximately 3,300 employees located in 12+ countries, Paysafe connects businesses and consumers across 100 payment types in over 40 currencies around the world. Delivered through an integrated platform, Paysafe solutions are geared toward mobile-initiated transactions, real-time analytics and the convergence between brick-and-mortar and online payments. Further information is available at www.paysafe.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240307401699/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom